Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis.
Nephron
; 144(9): 453-458, 2020.
Article
en En
| MEDLINE
| ID: mdl-32721954
ABSTRACT
IgA vasculitis can present as a glomerulonephritis histologically indistinguishable from IgA nephropathy (IgAN). In IgAN, the alternative and lectin pathways mediate glomerular injury and contribute to kidney function decline. Narsoplimab is a monoclonal antibody against mannan-binding lectin serine peptidase 2 (MASP-2), a key component of the lectin pathway. It is being evaluated in a phase III trial in IgAN (NCT03608033). Histopathological similarities with IgAN suggest lectin pathway activation also occurs in IgAV-associated nephritis (IgAVN). Here, we report the first ever case of narsoplimab use for the treatment of IgAVN.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Vasculitis
/
Proteínas del Sistema Complemento
/
Anticuerpos Monoclonales Humanizados
/
Glomerulonefritis por IGA
/
Lectinas
/
Anticuerpos Monoclonales
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Nephron
Año:
2020
Tipo del documento:
Article